Jun 12, 2024 · Allogeneic double-negative T cells (DNTs) are a rare T-cell subset that effectively target acute myeloid leukemia (AML) without inducing graft-versus-host disease in an allogeneic setting. A phase 1 clinical trial demonstrated the feasibility, safety, and potential efficacy of allogeneic DNT therapy among patients with relapsed AML.

Apr 24, 2018 · We have recently shown that allogeneic double negative T cells (DNTs) are able to target the majority of primary AML blasts in vitro and in patient-derived xenograft models. However, some primary AML blast samples are resistant to DNT cell therapy.

In this study, we explored a non-conventional T cell subset named double negative T cells (DNTs) as a novel therapy to target AML, including leukemic cells that are resistant to the conventional chemotherapy. DNTs are mature peripheral T lymphocytes expressing CD3-T cell receptor (TCR) complex but not CD4, CD8, nor invariant NK T cell markers.

Apr 22, 2021 · Double-negative T cells (DNTs) are peripheral mature T cells that express CD3, but not CD4, CD8, or invariant natural killer T-cell markers.

The expanded DNT cells could effectively kill both allogeneic and autologous primary CD34 + leukemic blasts isolated from peripheral blood of AML patients in a perforin-dependant manner.

Apr 1, 2019 · To expand clinical-grade healthy donor-derived double-negative T cells (DNT) to a therapeutically relevant number and characterize their potential to be used as an “off-the-shelf” adoptive cellular therapy (ACT) against cancers.

CD34 immunoreactivity was more frequently observed in non-specific DNT types (16/18 cases; 88.9%) than in classic types (6/23 cases; 26.1%) (P < 0.001). Peritumoral CD34 expression of non-neoplastic cells was significantly associated with CD34-positive tumours (20/22 cases; 90.9%) than with CD34-negative tumours (3/19 cases; 15.8%) (P < 0.001).

CD34 is primarily known as a biomarker for hematopoietic stem cells (HSCs) and hematopoietic stem precursor cells, but it has also been identified as a marker for several non-hematopoietic cells.

The tumor types included ganglioglioma (GG, number = 21), dysembryoplastic neuroepithelial tumor (DNT, number = 8), tumors/lesions which had the transitional features that between glioneuronal hamartia and mixed neuronal-glial tumor (number = 21) and pleomorphic xanthoastrocytoma (PXA, number = 4).

Sep 15, 1999 · CD34 + AML-M2 cells with chromosome 7 monosomy were cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF ), and interleukin-4 (IL-4). After 3 weeks of culture, 35% of the AML-M2 cells showed DC morphology and phenotype.